Overview

This trial is active, not recruiting.

Conditions leukemia, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive, philadelphia chromosome, hematologic diseases
Treatment radotinib
Phase phase 1/phase 2
Sponsor Il-Yang Pharm. Co., Ltd.
Start date July 2008
End date October 2012
Trial size 85 participants
Trial identifier NCT01602952, IY5511A1201

Summary

A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated phases.

Phase 1

1. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.

Phase 2

1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.

2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Phase 1 : 200mg/kg or 1200mg/m^2 Phase 2 : 400mg Bid
radotinib IY5511HCl
50mg, 100mg or 200mg Capsule BID

Primary Outcomes

Measure
To investigate the Maximum Tolerated Dose(Phase 1)
time frame: 12 month
Rate of Complete hematologic response(CHR)(Phase 2)
time frame: 12 months

Secondary Outcomes

Measure
To investigate the Dose Limiting Toxicity(Phase 1)
time frame: 12 months
Rate of complete Cytogenetic Response(CCyR)(Phase 2)
time frame: 12 months
Adverse events(Phase 1& Phase 2)
time frame: 12 months
Progression-free survival or PFS
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: Phase I 1. Age ≥ 18 years old 2. Ph+ CML patients who are resistant at chronic, accelerate, and acute phase, or suboptimal responsive, or intolerant to imatinib or resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously. 3. WHO Performance status of ≤2 4. Patients must have the following laboratory values With normal liver and renal function 5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug. Phase II 1. Age ≥ 18 years old 2. Ph+ CML patients in chronic or accelerated phase who are resistant or intolerant to Imatinib mesylate 3. WHO Performance status of ≤2 4. Patients must have the following laboratory values With normal liver and renal function 5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug. Exclusion Criteria: Phase I 1. CNS infiltration 2. Impaired cardiac function, including any one of the followings. - LVEF <45% as determined by MUGA scan or echocardiogram - Clinically significant resting bradycardia 3. Severe GI disease that may cause drug absorption problem of study drug 4. Use of therapeutic Warfarin 5. Acute or chronic liver or renal disease 6. Other concurrent severe and/or uncontrolled medical conditions 7. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug. 8. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval 9. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week 10. Patients who have received Nilotinib and Dasatinib ≤4 weeks prior to starting study drug. 11. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy 12. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control. 13. Patients not to agree using birth control during the study and for up 3 months following study completion. 15. HIV infection Phase II 1. Blast phase CML 2. CNS infiltration 3. Impaired cardiac function, including any one of the following - LVEF< 45% as determined by MUGA scan or echocardiogram - Use of Cardiac pacemaker - ST depression > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads - Congenital long QT syndrome - History of, or presence of significant ventricular or atrial tachyarrhythmias - Clinically significant resting bradycardia - QTcF> 480 msec on screening ECG - Right bundle branch block + left anterior hemiblock, Bifascicular block - Angina pectoris 4. Severe GI disease that may cause drug absorption problem of study 5. Use of therapeutic Warfarin 6. Acute or chronic liver or renal disease 7. Other concurrent severe and/or uncontrolled medical conditions 8. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug. 9. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval 10. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week 11. Patients who have received wide field radiotherapy ≤4 weeks prior to starting study drug. 12. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy 13. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control

Additional Information

Official title A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)
Description This study is a multi-center, open-label, Phase 1/2 clinical trial of Radotinib HCl, a targeted anticancer agent that inhibits the Bcr-Abl oncoprotein. It is aimed at determining the optimal therapeutic dose and confirming safety and efficacy of Radotinib HCl. Phase 1 study began at St. Mary's hospital in Korea and Phase 2 study is ongoing at 9 Korean sites and about 7 sites in China, India and Thailand will take part in Phase 2. After determination of a safe and proper therapeutic dose in Phase 1, Phase 2 began continuously to evaluate efficacy in chronic and accelerated phases. Before the start of the Phase 2 trial, interim or final reports for the Phase 1 trial were reviewed by the Korean Food and Drug Administration.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Il-Yang Pharm. Co., Ltd..